The global RAC gamma serine/threonine-protein kinase market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). AKT3 is one of three closely related serine/threonine-protein kinases (AKT1, AKT2, and AKT3) that regulate a variety of functions including metabolism, cell survival, growth, and angiogenesis. This is accomplished by phosphorylating a variety of downstream substrates with serine and/or threonine. So far, over 100 substrate candidates have been reported, however, none of them have been shown to be isoform-specific. AKT3 is the AKT isoform that has received the least amount of research. It is essential for the viability of malignant glioma cells and plays a critical function in brain development. The expression of the phosphorylated form of Bcl-2 agonist of cell death (BAD) is reduced by RNA interference, resulting in caspase-dependent apoptosis induction.

Additionally, based on the application the RAC gamma serine-threonine protein kinase market is segmented into breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, and others. The breast cancer segment is expected to hold a lucrative share in the market during the forecast period. Breast cancer is the second most common cancer, globally. According to the WHO, breast cancer held 11.7% of new cases in all types of cancers in 2020. Breast cancer is the most common cancer in women both in developed and emerging economies. Emerging economies have the highest number of breast cancer incidences due to a sedentary lifestyle and lack of awareness regarding the disease. In Asia, 10,26,171 new cases of breast cancer were reported in 2020 with approximately 346,009 mortalities. The high incidence related to breast cancer in women across the globe is primarily driving the growth of the segment. 

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Type
• By Application

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- Merck & Co., Inc., AstraZeneca Plc, and Novartis International AG among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global RAC Gamma Serine/Threonine Protein Kinase Market Report by Segment

By Type 

• MK-2206
• JRP-890
• ISC-4
• AZD-5363.

By Application 

• Breast Cancer
• Endometrial Cancer
• Non-Small Cell Lung Cancer
• Ovarian Cancer
• Cervical Cancer
• Others 

Global RAC Gamma Serine/Threonine Protein Kinase Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific 

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa